Natural Investments LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Natural Investments LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,987 shares of the biopharmaceutical company's stock, valued at approximately $460,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new stake in Gilead Sciences during the 4th quarter worth about $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $29,000. Crews Bank & Trust purchased a new position in shares of Gilead Sciences in the 4th quarter valued at about $31,000. Finally, Stephens Consulting LLC raised its position in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 260 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $114.43 on Wednesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm's 50-day simple moving average is $100.56 and its 200 day simple moving average is $92.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The stock has a market cap of $142.50 billion, a price-to-earnings ratio of 309.27, a PEG ratio of 0.71 and a beta of 0.21.

Remove Ads

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.76%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences's payout ratio is presently 854.05%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 8,500 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the completion of the sale, the chief financial officer now owns 132,373 shares of the company's stock, valued at $12,173,021.08. The trade was a 6.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 293,356 shares of company stock worth $29,166,240 in the last three months. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Piper Sandler upped their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Citigroup began coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They issued a "buy" rating and a $125.00 price objective for the company. Cantor Fitzgerald reissued a "neutral" rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company lifted their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $104.52.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.